



October 21, 2004

Celsion to Present at Rodman & Renshaw Techvest 6th Annual Healthcare Conference

COLUMBIA, Md.--(BUSINESS WIRE)--Oct. 21, 2004--CELSION CORPORATION (AMEX:CLN) announced that its Executive Vice President and Chief Operating Officer, Tony Deasey, is scheduled to appear as a featured presenter at the Rodman & Renshaw Techvest 6th Annual Healthcare Conference taking place October 26-28, 2004, in New York, New York. His presentation is scheduled for 10:25 a.m. (ET) on October 27, 2004. The presentation will be available live by webcast and available for a 90-day period thereafter. The webcast can be accessed at the following link:

<http://www.rodmanandrenshaw.com/rodman.asp?link=Conferences3/ConferenceMain&bgcolor=wht> (Due to its length, this URL may need to be copied/pasted into your Internet browser's address field. Remove the extra space if one exists.)

ABOUT CELSION: Celsion Corporation, based in Columbia, Maryland, is a biotechnology company dedicated to the development and commercialization of treatment systems for cancer and other diseases using focused-heat energy, either administered alone, or in combination with other therapeutic devices, heat activated genes and heat activated drugs.

Celsion has research, license or commercialization agreements with leading institutions such as the National Institute of Health, Duke University Medical Center, Massachusetts Institute of Technology, Harbor UCLA Medical Center, Montefiore Medical Center and Memorial Sloan-Kettering Cancer Center in New York City, Roswell Park Cancer Institute in Buffalo, New York, and Duke University. For more information on Celsion, visit our website: www.celsion.com.

Celsion wishes to inform readers that forward-looking statements in this release are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Readers are cautioned that such forward-looking statements involve risks and uncertainties including, without limitation, unforeseen changes in the course of research and development activities and in clinical trials by others; possible acquisitions of other technologies, assets or businesses; possible actions by customers, suppliers, competitors, regulatory authorities; and other risks detailed from time to time in the Company's periodic reports filed with the Securities and Exchange Commission.

CONTACT: Celsion Corporation
Tony Deasey, 410-290-5390
tony@celsion.com
or
Equity Communications
Steve Chizzik/Ira Weingarten
973-912-0980
chizzl@comcast.net
or
StrategicGrowth International, Inc.
Jennifer Zimmons, 212-838-1444
info@sgi-ir.com

SOURCE: Celsion Corporation